Bristol Myers and BioNTech Report Early Lung-Cancer Trial Results - FINCHANNEL

Bristol Myers and BioNTech report early lung-cancer trial results - FINCHANNEL

Bristol Myers and BioNTech report early lung-cancer trial results

Pumitamig Combo Yields Activity in Metastatic Non–Small Cell Lung Cancer

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.

BioNTech reports 36.7% response in pumitamig lung trial

BioNTech and Bristol Myers report 36.7% confirmed response with pumitamig plus docetaxel in 30 evaluable patients, without a control arm.

Pfizer looks beyond lung cancer flop as BioNTech, BMS show early activity

Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis. Also on Sunday, BioNTech and Bristol Myers Squibb touted early lung cancer data for their PD-L1×VEGF bispecific pumitamig.

BioNTech and Bristol Myers Squibb's lung cancer drug combo showed a median of 6.9 months before disease worsened.

Among 30 evaluable patients, 90% had disease control after progression on immunotherapy plus chemotherapy; results will inform pumitamig’s further development.